{"protocolSection": {"identificationModule": {"nctId": "NCT02573155", "orgStudyIdInfo": {"id": "D6640C00001"}, "secondaryIdInfos": [{"id": "2015-002906-36", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects", "officialTitle": "A 2-part, Randomised, Placebo-controlled, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of AZD8871 Delivered by Inhalation in Asthmatic and Chronic Obstructive Pulmonary Disease (COPD) Subjects"}, "statusModule": {"statusVerifiedDate": "2018-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-10"}, "primaryCompletionDateStruct": {"date": "2016-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-10-08", "studyFirstSubmitQcDate": "2015-10-08", "studyFirstPostDateStruct": {"date": "2015-10-09", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-08-22", "resultsFirstSubmitQcDate": "2018-04-06", "resultsFirstPostDateStruct": {"date": "2018-11-08", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-04-06", "lastUpdatePostDateStruct": {"date": "2018-11-08", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This is a phase I, randomised, placebo-controlled 2-part study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8871 delivered by inhalation, in asthmatic and chronic obstructive pulmonary disease (COPD) subjects.", "detailedDescription": "This study is an integrated Phase I protocol divided into 2 parts.\n\nPart 1: single ascending dose study (6 AZD8871 dose levels) in 16 male subjects with mild asthma. AZD8871 will be administered (by the Genuair\u00ae inhaler) under supervision at the study centre, according to the randomisation scheme\n\nPart 2: a 5 treatment period single dose study (of AZD8871 \\[two doses\\], indacaterol, tiotropium and placebo) in 40 male and non-childbearing female subjects with moderate to severe COPD. Each treatment period will be separated by a washout period of at least 7 days. The primary comparison for bronchodilation will be between AZD8871 doses and placebo."}, "conditionsModule": {"conditions": ["Asthma (Part 1)", "COPD (Part 2)"], "keywords": ["Pharmacokinetics", "Pharmacodynamics", "AZD8871", "Safety", "Tolerability", "mild persistent asthma", "moderate to severe COPD"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["PARTICIPANT"]}}, "enrollmentInfo": {"count": 134, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sequence 1, Part 1", "type": "EXPERIMENTAL", "description": "Period 1: Dose 1 Period 2: Dose 3 Period 3: Dose 5", "interventionNames": ["Drug: Dose 1, AZD8871 50 \u03bcg (Part 1)", "Drug: Dose 3, AZD8871 300 \u03bcg (Part 1)", "Drug: Dose 5, AZD8871 1200 \u00b5g (Part 1)"]}, {"label": "Sequence 2, Part 1", "type": "EXPERIMENTAL", "description": "Period 1: Placebo Period 2: Dose 3 Period 3: Dose 5", "interventionNames": ["Drug: Dose 3, AZD8871 300 \u03bcg (Part 1)", "Drug: Dose 5, AZD8871 1200 \u00b5g (Part 1)", "Drug: Placebo, AZD8871 placebo (Part 1)"]}, {"label": "Sequence 3, Part 1", "type": "EXPERIMENTAL", "description": "Period 1: Dose 1 Period 2: Placebo Period 3: Dose 5", "interventionNames": ["Drug: Dose 1, AZD8871 50 \u03bcg (Part 1)", "Drug: Dose 5, AZD8871 1200 \u00b5g (Part 1)", "Drug: Placebo, AZD8871 placebo (Part 1)"]}, {"label": "Sequence 4, Part 1", "type": "EXPERIMENTAL", "description": "Period 1: Dose 1 Period 2: Dose 3 Period 3: Placebo", "interventionNames": ["Drug: Dose 1, AZD8871 50 \u03bcg (Part 1)", "Drug: Dose 3, AZD8871 300 \u03bcg (Part 1)", "Drug: Placebo, AZD8871 placebo (Part 1)"]}, {"label": "Sequence 5, Part 1", "type": "EXPERIMENTAL", "description": "Period 1: Dose 2 Period 2: Dose 4 Period 3: Dose 6", "interventionNames": ["Drug: Dose 2, AZD8871 100 \u03bcg (Part 1)", "Drug: Dose 4, AZD8871 600 \u00b5g (Part 1)", "Drug: Dose 6, AZD8871 1800 \u03bcg (Part 1)"]}, {"label": "Sequence 6, Part 1", "type": "EXPERIMENTAL", "description": "Period 1: Placebo Period 2: Dose 4 Period 3: Dose 6", "interventionNames": ["Drug: Dose 4, AZD8871 600 \u00b5g (Part 1)", "Drug: Dose 6, AZD8871 1800 \u03bcg (Part 1)", "Drug: Placebo, AZD8871 placebo (Part 1)"]}, {"label": "Sequence 7, Part 1", "type": "EXPERIMENTAL", "description": "Period 1: Dose 2 Period 2: Placebo Period 3: Dose 6", "interventionNames": ["Drug: Dose 2, AZD8871 100 \u03bcg (Part 1)", "Drug: Dose 6, AZD8871 1800 \u03bcg (Part 1)", "Drug: Placebo, AZD8871 placebo (Part 1)"]}, {"label": "Sequence 8, Part 1", "type": "EXPERIMENTAL", "description": "Period 1: Dose 2 Period 2: Dose 4 Period 3: Placebo", "interventionNames": ["Drug: Dose 2, AZD8871 100 \u03bcg (Part 1)", "Drug: Dose 4, AZD8871 600 \u00b5g (Part 1)", "Drug: Placebo, AZD8871 placebo (Part 1)"]}, {"label": "Sequence 1, Part 2", "type": "EXPERIMENTAL", "description": "Period 1: Treatment A Period 2: Treatment B Period 3: Treatment E Period 4: Treatment C Period 5: Treatment D", "interventionNames": ["Drug: Treatment A, AZD8871 dose A (Part 2)", "Drug: Treatment B, AZD8871 dose B (Part 2)", "Drug: Treatment C, Indacaterol 150 \u03bcg (Part 2)", "Drug: Treatment D, Tiotropium 18 \u03bcg (Part 2)"]}, {"label": "Sequence 2, Part 2", "type": "EXPERIMENTAL", "description": "Period 1: Treatment B Period 2: Treatment C Period 3: Treatment A Period 4: Treatment D Period 5: Treatment E", "interventionNames": ["Drug: Treatment A, AZD8871 dose A (Part 2)", "Drug: Treatment B, AZD8871 dose B (Part 2)", "Drug: Treatment C, Indacaterol 150 \u03bcg (Part 2)", "Drug: Treatment D, Tiotropium 18 \u03bcg (Part 2)"]}, {"label": "Sequence 3, Part 2", "type": "EXPERIMENTAL", "description": "Period 1: Treatment C Period 2: Treatment D Period 3: Treatment B Period 4: Treatment E Period 5: Treatment A", "interventionNames": ["Drug: Treatment A, AZD8871 dose A (Part 2)", "Drug: Treatment B, AZD8871 dose B (Part 2)", "Drug: Treatment C, Indacaterol 150 \u03bcg (Part 2)", "Drug: Treatment D, Tiotropium 18 \u03bcg (Part 2)"]}, {"label": "Sequence 4, Part 2", "type": "EXPERIMENTAL", "description": "Period 1: Treatment D Period 2: Treatment E Period 3: Treatment C Period 4: Treatment A Period 5: Treatment B", "interventionNames": ["Drug: Treatment A, AZD8871 dose A (Part 2)", "Drug: Treatment B, AZD8871 dose B (Part 2)", "Drug: Treatment C, Indacaterol 150 \u03bcg (Part 2)", "Drug: Treatment D, Tiotropium 18 \u03bcg (Part 2)"]}, {"label": "Sequence 5, Part 2", "type": "EXPERIMENTAL", "description": "Period 1: Treatment E Period 2: Treatment A Period 3: Treatment D Period 4: Treatment B Period 5: Treatment C", "interventionNames": ["Drug: Treatment A, AZD8871 dose A (Part 2)", "Drug: Treatment B, AZD8871 dose B (Part 2)", "Drug: Treatment C, Indacaterol 150 \u03bcg (Part 2)", "Drug: Treatment D, Tiotropium 18 \u03bcg (Part 2)"]}, {"label": "Sequence 6, Part 2", "type": "EXPERIMENTAL", "description": "Period 1: Treatment D Period 2: Treatment C Period 3: Treatment E Period 4: Treatment B Period 5: Treatment A", "interventionNames": ["Drug: Treatment A, AZD8871 dose A (Part 2)", "Drug: Treatment B, AZD8871 dose B (Part 2)", "Drug: Treatment C, Indacaterol 150 \u03bcg (Part 2)", "Drug: Treatment D, Tiotropium 18 \u03bcg (Part 2)"]}, {"label": "Sequence 7, Part 2", "type": "EXPERIMENTAL", "description": "Period 1: Treatment E Period 2: Treatment D Period 3: Treatment A Period 4: Treatment C Period 5: Treatment B", "interventionNames": ["Drug: Treatment A, AZD8871 dose A (Part 2)", "Drug: Treatment B, AZD8871 dose B (Part 2)", "Drug: Treatment C, Indacaterol 150 \u03bcg (Part 2)", "Drug: Treatment D, Tiotropium 18 \u03bcg (Part 2)"]}, {"label": "Sequence 8, Part 2", "type": "EXPERIMENTAL", "description": "Period 1: Treatment A Period 2: Treatment E Period 3: Treatment B Period 4: Treatment D Period 5: Treatment C", "interventionNames": ["Drug: Treatment A, AZD8871 dose A (Part 2)", "Drug: Treatment B, AZD8871 dose B (Part 2)", "Drug: Treatment C, Indacaterol 150 \u03bcg (Part 2)", "Drug: Treatment D, Tiotropium 18 \u03bcg (Part 2)"]}, {"label": "Sequence 9, Part 2", "type": "EXPERIMENTAL", "description": "Period 1: Treatment B Period 2: Treatment A Period 3: Treatment C Period 4: Treatment E Period 5: Treatment D", "interventionNames": ["Drug: Treatment A, AZD8871 dose A (Part 2)", "Drug: Treatment B, AZD8871 dose B (Part 2)", "Drug: Treatment C, Indacaterol 150 \u03bcg (Part 2)", "Drug: Treatment D, Tiotropium 18 \u03bcg (Part 2)"]}, {"label": "Sequence 10, Part 2", "type": "EXPERIMENTAL", "description": "Period 1: Treatment C Period 2: Treatment B Period 3: Treatment D Period 4: Treatment A Period 5: Treatment E", "interventionNames": ["Drug: Treatment A, AZD8871 dose A (Part 2)", "Drug: Treatment B, AZD8871 dose B (Part 2)", "Drug: Treatment C, Indacaterol 150 \u03bcg (Part 2)", "Drug: Treatment D, Tiotropium 18 \u03bcg (Part 2)"]}], "interventions": [{"type": "DRUG", "name": "Dose 1, AZD8871 50 \u03bcg (Part 1)", "description": "50 \u00b5g of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair\u00ae)", "armGroupLabels": ["Sequence 1, Part 1", "Sequence 3, Part 1", "Sequence 4, Part 1"]}, {"type": "DRUG", "name": "Dose 2, AZD8871 100 \u03bcg (Part 1)", "description": "100 \u00b5g of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair\u00ae)", "armGroupLabels": ["Sequence 5, Part 1", "Sequence 7, Part 1", "Sequence 8, Part 1"]}, {"type": "DRUG", "name": "Dose 3, AZD8871 300 \u03bcg (Part 1)", "description": "300 \u00b5g of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair\u00ae)", "armGroupLabels": ["Sequence 1, Part 1", "Sequence 2, Part 1", "Sequence 4, Part 1"]}, {"type": "DRUG", "name": "Dose 4, AZD8871 600 \u00b5g (Part 1)", "description": "600 \u00b5g of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair\u00ae)", "armGroupLabels": ["Sequence 5, Part 1", "Sequence 6, Part 1", "Sequence 8, Part 1"]}, {"type": "DRUG", "name": "Dose 5, AZD8871 1200 \u00b5g (Part 1)", "description": "1200 \u00b5g of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair\u00ae)", "armGroupLabels": ["Sequence 1, Part 1", "Sequence 2, Part 1", "Sequence 3, Part 1"]}, {"type": "DRUG", "name": "Dose 6, AZD8871 1800 \u03bcg (Part 1)", "description": "1800 \u00b5g of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair\u00ae)", "armGroupLabels": ["Sequence 5, Part 1", "Sequence 6, Part 1", "Sequence 7, Part 1"]}, {"type": "DRUG", "name": "Placebo, AZD8871 placebo (Part 1)", "description": "AZD8871 placebo on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair\u00ae)", "armGroupLabels": ["Sequence 2, Part 1", "Sequence 3, Part 1", "Sequence 4, Part 1", "Sequence 6, Part 1", "Sequence 7, Part 1", "Sequence 8, Part 1"]}, {"type": "DRUG", "name": "Treatment A, AZD8871 dose A (Part 2)", "description": "AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair\u00ae)", "armGroupLabels": ["Sequence 1, Part 2", "Sequence 10, Part 2", "Sequence 2, Part 2", "Sequence 3, Part 2", "Sequence 4, Part 2", "Sequence 5, Part 2", "Sequence 6, Part 2", "Sequence 7, Part 2", "Sequence 8, Part 2", "Sequence 9, Part 2"]}, {"type": "DRUG", "name": "Treatment B, AZD8871 dose B (Part 2)", "description": "AZD8871 dose B once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler(Genuair\u00ae)", "armGroupLabels": ["Sequence 1, Part 2", "Sequence 10, Part 2", "Sequence 2, Part 2", "Sequence 3, Part 2", "Sequence 4, Part 2", "Sequence 5, Part 2", "Sequence 6, Part 2", "Sequence 7, Part 2", "Sequence 8, Part 2", "Sequence 9, Part 2"]}, {"type": "DRUG", "name": "Treatment C, Indacaterol 150 \u03bcg (Part 2)", "description": "150 \u03bcg of Indacaterol once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (Onbrez Breezhaler\u00ae) as 1 hard capsule", "armGroupLabels": ["Sequence 1, Part 2", "Sequence 10, Part 2", "Sequence 2, Part 2", "Sequence 3, Part 2", "Sequence 4, Part 2", "Sequence 5, Part 2", "Sequence 6, Part 2", "Sequence 7, Part 2", "Sequence 8, Part 2", "Sequence 9, Part 2"]}, {"type": "DRUG", "name": "Treatment D, Tiotropium 18 \u03bcg (Part 2)", "description": "18 \u03bcg of Tiotropium once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (HandiHaler\u00ae) as 1 hard capsule", "armGroupLabels": ["Sequence 1, Part 2", "Sequence 10, Part 2", "Sequence 2, Part 2", "Sequence 3, Part 2", "Sequence 4, Part 2", "Sequence 5, Part 2", "Sequence 6, Part 2", "Sequence 7, Part 2", "Sequence 8, Part 2", "Sequence 9, Part 2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The Number of Participants With Mild Persistent Asthma (Part 1) and COPD (Part 2) With at Least 1 Treatment-emergent Adverse Event", "description": "An adverse event is the development of an undesirable medical condition, or the deterioration of a pre-existing medical condition, following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. An undesirable medical condition can be symptoms, signs, or the abnormal results of laboratory parameters (haematology, blood chemistry, urinalysis, physical examination, 12-lead ECGs and telemetry, and vital signs). AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 18.1.", "timeFrame": "From the time of informed consent up to 14 (\u00b12) days after the last dose of investigational product. Unresolved AEs were followed up by the investigator for as long as medically indicated."}, {"measure": "Number of Participants With Clinically Relevant Abnormalities in Blood Pressure", "description": "Blood pressure (BP) measurements (diastolic \\[DBP\\] and systolic BP \\[SBP\\]) taken after \\~5 minutes rest in supine position, at screening, baseline (\u22641 hour before IP administration), 10 and 30 minutes, 1, 2, 3, 4, 8, 12 hours (Day 1) and 24 and 36 hours (Day 2) after IP administration. Normal BP at screening: SBP 100-140 mmHg (subjects aged \u226459 years) and 100-150 mmHg (subjects aged \u226560 years), and DBP 40-90 mmHg.\n\nCriteria for notable changes in BP:\n\nHigh SBP: (\u2265180 and increase over baseline (predose) \u226520) or (\u2265200 and baseline \\<200) Low SBP: (\u2264 90 and decrease over baseline \u226520) or (\u226475 and baseline \\>75) High DBP: (\u2265105 and increase over baseline \u226515) or (\u2265115 and baseline \\<115) Low DBP: (\u226450 and decrease over baseline \u226515) or (\u226440 and baseline \\>40) All out of range values were flagged to the principal investigator who assessed clinical relevance based on medical criteria at individual subject level. Clinically relevant findings were assessed until considered non-clinically relevant.", "timeFrame": "From the time of informed consent up to 36 hours after last dose of IP."}, {"measure": "Number of Participants With Clinically Relevant Abnormalities in Electrocardiograms (HR, QTcF and Other ECG Parameters).", "description": "HR, QTcF and other ECG abnormalities were assessed by local digital 12-lead ECG performed in triplicate at the time points indicated:\n\nECG (Parts 1 and 2) was assessed at Screening, Day 1 baseline, 10 min, 30 min, 1 hour (h), 2 h, 3 h, 4 h, 8 h, 12 h, 24 h, 36 h after dosing.\n\nTelemetry (Part 1), assessed with at least 2 lead real time display, was recorded at Day -1 (4-6 hours continuous recording, at the time this was more convenient for the logistics of the unit) and on Day 1 from the time of the IP administration up to at least 24 hours, but if advised by the Investigator or designee, then up to 36 hours after IP administration.\n\nAbnormal findings were flagged to the principal investigator who assessed clinical relevance based on medical criteria at individual subject level. Clinically relevant findings were assessed until the abnormality was considered non-clinically relevant.", "timeFrame": "From the time of informed consent up to 36 hours after last dose of IP."}, {"measure": "Number of Participants With Clinically Relevant Abnormalities in Clinical Biochemistry, Hematology and Urinalysis", "description": "A composite of clinically relevant abnormalities in clinical biochemistry, hematology and urinalysis laboratory evaluations. Laboratory tests (haematology, blood chemistry, and urinalysis) were performed at screening, at Day -1 (Part 1 only), at 24 hours (Day 2) and at follow-up (7 \\[\u00b12\\] days) after IP administration. Coagulation was only performed at screening; TSH, T4 only at screening, at Day-1 and at follow-up.\n\nAbnormal findings were flagged to the principal investigator who assessed clinical relevance based on medical criteria at individual subject level. Clinically relevant findings were assessed until the abnormality was considered non-clinically relevant.", "timeFrame": "From the time of informed consent up to 7 days after the last dose of IP."}, {"measure": "Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) on Day 2", "description": "Pharmacodynamics of AZD8871 before (-45 min and -15 min pre-dose) and after single dosing of AZD8871 Forced expiratory volume in 1 second (FEV1) on Day 2 (defined as the average of the values 23:00 and 24:00 hours after the morning dose of investigational product)", "timeFrame": "Baseline (Day 1) to 36 hours post-dose (Day 2)"}], "secondaryOutcomes": [{"measure": "Cmax of AZD8871 in Parts 1 and 2", "description": "Cmax (maximum observed plasma drug concentrations) of AZD8871 on Day 1 of each treatment period.", "timeFrame": "Pre-dose, and 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h, and 36 h (Day 2) post-dose"}, {"measure": "Tmax of AZD8871 in Parts 1 and 2", "description": "tmax (time to reach maximum concentration) of AZD8871 on Day 1 of each treatment period.", "timeFrame": "Pre-dose, and 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h, and 36 h (Day 2) post-dose"}, {"measure": "AUC(0-t) of AZD8871 in Parts 1 and 2", "description": "AUC(0-t) (area under the concentration-time curve from time zero to time of the last quantifiable measurable concentration) of AZD8871 on Day 1 of each treatment period.", "timeFrame": "Pre-dose, and 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h, and 36 h (Day 2) post-dose"}, {"measure": "AUC(0-24) of AZD8871 in Parts 1 and 2", "description": "AUC(0-24) (area under the concentration-time curve from zero to 24h) of AZD8871 on Day 1 of each treatment period.", "timeFrame": "Pre-dose, and 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h, and 36 h (Day 2) post-dose"}], "otherOutcomes": [{"measure": "AUC of AZD8871 in Parts 1 and 2", "description": "AUC (area under the concentration-time curve from time 0 to infinity) of AZD8871 on Day 1 of each treatment period", "timeFrame": "Predose, and 5 min, 15 min, 30 min, and 45 min, at 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h and 36 h (Day 2) post-dose"}, {"measure": "Elimination Half-life of AZD8871 in Parts 1 and 2", "description": "Elimination half-life (t\u00bd\u03bbz) for AZD8871 on Day 1 of each treatment period. t\u00bd\u03bbz was generally calculated over a period of less than 3 times the resultant half-life", "timeFrame": "Predose, and 5 min, 15 min, 30 min, and 45 min, at 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h and 36 h (Day 2) post-dose"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:Part 1\n\n1. Subjects who are able and willing to provide written informed consent prior to conducting any study-related procedures, including withdrawal of medications\n2. Adult male subjects aged 18 to 70 years (both inclusive)\n3. Body mass index (BMI) from 18 to 32 kg/m2 at screening\n4. Clinical diagnosis of asthma (according to the Global Initiative for Asthma \\[GINA\\] guidelines) for at least 6 months prior to screening\n5. Ability to change current asthma therapy, to discontinue previous prescribed medications after signature of informed consent as per required washout periods\n6. Screening FEV1 value of \u226570% of the predicted normal value\n7. FEV1 reversibility of \u226512% and an absolute increase of at least 200 mL over the baseline value within 30 min after inhalation of 400 \u00b5g (4 puffs) of salbutamol via a metered dose inhaler, with spacer device\n8. Subjects using intermittent salbutamol and / or subjects on a stable dose of low dose Inhaled corticosteroid (as defined by the GINA guidelines) at least 4 weeks prior to screening\n9. Predose FEV1 value of first treatment period within the range of \u00b1 20% of the FEV1 measured at screening prior to salbutamol inhalation\n10. No current smokers, no subjects with a smoking history during the last 12 months and no subjects with a total smoking history of more than 10 pack-years\n11. No other relevant pulmonary disease or history of thoracic surgery\n12. Subjects who are otherwise healthy as determined by medical history, physical examination, 12-lead ECG findings\n13. Normal blood pressure (defined as Systolic blood pressure \\[SBP\\] between 100 and 140 mmHg for subjects \u226459 years of age and between 100 and 150 mmHg for subjects \u226560 years of age, and Diastolic blood pressure \\[DBP\\] between 40 and 90 mmHg) at screening\n14. Subjects whose clinical laboratory test results are not clinically relevant and are acceptable to the Investigator.\n15. Subjects who are negative for hepatitis B surface antigen (HBsAg), hepatitis B core (HBc) antibody (IgM), hepatitis C antibody and human immunodeficiency virus (HIV) I and II antibodies at screening\n16. Subjects who are negative for drugs of abuse and alcohol tests at screening and admission\n17. Subjects able to perform repeatable pulmonary function testing for FEV1 according to the American Thoracic Society (ATS) / European Respiratory Society (ERS) 2005(9) criteria at screening\n\nInclusion Criteria: Part 2\n\n1. Adult male and non-childbearing female subjects aged \u226540 years with a clinical diagnosis of stable moderate to severe COPD according to GOLD guidelines at screening\n2. Females must be of non-childbearing potential, confirmed at screening by fulfilling study predefined criteria\n3. Post-salbutamol FEV1 \\<80% and \u226530% of the predicted normal value and post-salbutamol FEV1 / forced vital capacity (FVC) \\<70%\n4. BMI \\< 40 kg/m2 at screening\n5. Ability to change current COPD therapy, to discontinue previous prescribed medications after signature of informed consent as per required washout periods\n6. Current or ex-smokers with a smoking history of \u226510 pack years\n7. No evidence of clinically significant respiratory and / or cardiovascular conditions (e.g. uncontrolled hypertension) or laboratory abnormalities\n8. No other relevant pulmonary disease or history of thoracic surgery\n9. Subjects who are negative for HBsAg, HBc IgM, hepatitis C antibody and HIV I and II antibodies at screening\n10. Subjects who are able and willing to provide written informed consent prior to conducting any study-related procedures, including withdrawal of medications\n11. Medical history must be verified by either a personal physician or medical practitioner as appropriate\n12. Subjects able to perform repeatable pulmonary function testing for FEV1 according to the ATS / ERS 2005(9) criteria at screening\n\nExclusion Criteria (Part 1 \\& 2):\n\n1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)\n2. Previous enrolment or randomisation of treatment in the present study\n3. Current evidence or recent history of any clinically significant and unstable disease (other than asthma/COPD) or abnormality that could put the subject at risk or could confound the results of the study\n4. Subjects with a surgical history clinically relevant for the purpose of the study\n5. History of malignancy of any organ system, treated or untreated within the past 5 years, with the exception of localised basal cell carcinoma of the skin\n6. Subjects with serious adverse reaction or serious hypersensitivity to Tiotropium (for Part 2 only), Indacaterol (for Part 2 only), or the formulation excipients (eg, lactose) or other drugs in the same pharmacologic class (for Part 1 and Part 2)\n7. Current diagnosis of COPD (for Part 1 only) or history of / or current diagnosis for asthma (for Part 2 only)\n8. Recent history of asthma / COPD exacerbation requiring hospitalisation or need for increased maintenance treatments for asthma / COPD within 6 weeks prior to screening or prior to randomisation\n9. Use of daily oxygen therapy \\>10 h per day (for Part 2 only)\n10. Use of systemic steroids for respiratory reasons within 6 weeks prior to screening\n11. Lower respiratory tract infection within 6 weeks prior to screening or prior to randomisation\n12. Upper respiratory tract infection requiring antibiotics within 6 weeks prior to screening or prior to randomisation\n13. Current history of tuberculosis, bronchiectasis or other non-specific pulmonary disease\n14. Subject with significant cardiovascular disease that may be vulnerable to cardiovascular instability\n15. QTcF (QT interval corrected, Fridericia formula QT\\[msec\\]/RR\\[s\\]) interval, \\>450 ms for males and \\>470 ms for females at screening or prior to randomisation, or history of long QT syndrome\n16. PR (duration in milliseconds from the beginning of wave P to onset of ventricular depolarisation \\[Q or R\\]) interval \\>200 ms at screening or prior to randomisation (for Part 1 only) Note: 4- 6 hours of ECG rhythm monitoring with telemetry will be performed on Day-1 to identify patients that may have any clinical significant abnormality prior to randomisation. If this occurs, patients should not participate in the study\n17. Subjects with serum potassium concentration \\< 3.5mmol/l at screening\n18. Subjects with a history of excessive use or abuse of alcohol within the past 2 years\n19. Subjects with a history of drug abuse within the past 2 years\n20. Subjects who are positive for drugs of abuse and alcohol tests at screening and prior to randomisation. Subjects consuming more than 14 (female subjects) or 21 (male subjects) units of alcohol a week\n21. Donation or loss \\>400 ml of blood and plasma within the previous 3 months prior to screening\n22. Subjects with a significant infection or known inflammatory process at screening or prior to randomisation\n23. Subjects with acute gastrointestinal symptoms at the time of screening or prior to randomisation (eg, nausea, vomiting, diarrhoea, heartburn)\n24. Subjects with an acute infection such as influenza at the time of screening or prior to randomisation\n25. Male subjects who do not agree to follow instructions to avoid pregnancies\n26. Subjects who are not able to adhere to the restrictions on prior and concomitant medications\n27. Subjects who intend to use any concomitant medication not permitted by this protocol or who have not undergone the required washout period for a particular prohibited medication\n28. Subjects who have used any investigational drug within 3 months prior to screening or within the equivalent time of 6 half-lives of receiving the last administration, whichever is longer\n29. Subjects who have received the last dose of investigational product more than 3 months ago but who are on an extended follow-up\n30. Subjects who are unlikely to co-operate with the requirements of the study, or the study center or the subjects who are unwilling or unable to follow the instructions of the principal investigator", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "130 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Muna Albayaty, MBChB, MSc,MFPM", "affiliation": "PAREXEL Early Phase Clinical Unit, London, United Kingdom", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Dave Singh, Prof.", "affiliation": "The Medicines Evaluation Unit (MEU), Manchester, United Kingdom", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Harrow", "country": "United Kingdom", "geoPoint": {"lat": 51.57142, "lon": -0.33371}}, {"facility": "Research Site", "city": "Manchester", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}]}, "referencesModule": {"references": [{"pmid": "32907576", "type": "DERIVED", "citation": "Jimenez E, Astbury C, Albayaty M, Wahlby-Hamren U, Seoane B, Villarroel C, Pujol H, Bermejo MJ, Aggarwal A, Psallidas I. Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator. Respir Res. 2020 Sep 9;21(Suppl 1):211. doi: 10.1186/s12931-020-01470-5."}, {"pmid": "32907566", "type": "DERIVED", "citation": "Singh D, Balaguer V, Astbury C, Wahlby-Hamren U, Jimenez E, Seoane B, Villarroel C, Lei A, Aggarwal A, Psallidas I. Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator. Respir Res. 2020 Sep 9;21(Suppl 1):102. doi: 10.1186/s12931-020-01347-7."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "2-part study: Part 1: single ascending doses of AZD8871 (planned 50, 100, 300, 600, 1200, 1800 \u03bcg; actual dose 50, 200, 400, 900, 1800, 2100 \u03bcg) or placebo over 3 treatment periods; 2 cohorts (male; mild persistent asthma).\n\nPart 2: 5-way complete cross-over, single-dose; M/F, moderate/severe COPD; 2 doses of AZD8871, placebo, or 2 active controls.", "recruitmentDetails": "This study was conducted at 2 centres in the UK (one for each part). In part 1 of the study, the first patient was screened in October 2015 and the last patient visit was in March 2016. In part 2 of the study, the first patient was screened in April 2016 and the last patient visit was in August 2016.", "groups": [{"id": "FG000", "title": "Overall Population - Part 1", "description": "All individuals in Part 1 (patients who received single doses of AZD8871 \\[50, 400, 1800 \u03bcg for Cohort 1; 200, 900, 2100 \u03bcg for Cohort 2\\], or placebo, in 3 treatment periods separated by washout periods of 14 days)."}, {"id": "FG001", "title": "Overall Population - Part 2", "description": "All individuals involved in Part 2 (patients who received single doses of AZD8871 \\[400 and 1800 \u03bcg\\], placebo, indacaterol 150 \u03bcg, or tiotropium 18 \u03bcg, in 5 treatment periods separated by washout periods of 7-21 days."}], "periods": [{"title": "Treatment Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "38"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "38"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Washout Between Treatment Period 1 and 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "38"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "33"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "5"}]}], "dropWithdraws": [{"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}]}]}, {"title": "Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "33"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "33"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Washout Between Treatment Period 2 and 3", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "33"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "31"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Sponsor's decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}]}, {"title": "Period 3", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "31"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "31"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Washout Between Treatment Period 3 and 4", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Part 1 comprised 3 treatment periods only", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "31"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Part 1 comprised 3 treatment periods only", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "29"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Stability/variability criteria not met", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}, {"title": "Period 4", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Part 1 comprised 3 treatment periods only", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "29"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Part 1 comprised 3 treatment periods only", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "29"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Washout Between Treatment Period 4 and 5", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Part 1 comprised 3 treatment periods only", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "29"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Part 1 comprised 3 treatment periods only", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "28"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}, {"title": "Period 5", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Part 1 comprised 3 treatment periods only", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "28"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Part 1 comprised 3 treatment periods only", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "28"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All randomized subjects who received at least 1 dose of the investigational product in Parts 1 and 2, respectively.", "groups": [{"id": "BG000", "title": "Overall Population - Part 1", "description": "All individuals in Part 1 (patients who received single doses of AZD8871 \\[50, 400, 1800 \u03bcg for Cohort 1; 200, 900, 2100 \u03bcg for Cohort 2\\], or placebo, in 3 treatment periods separated by washout periods of 14 days)."}, {"id": "BG001", "title": "Overall Population - Part 2", "description": "All individuals involved in Part 2 (patients who received single doses of AZD8871 \\[400 and 1800 \u03bcg\\], placebo, indacaterol 150 \u03bcg, or tiotropium 18 \u03bcg, in 5 treatment periods separated by washout periods of 7-21 days."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "38"}, {"groupId": "BG002", "value": "54"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "39.0", "spread": "11.8"}, {"groupId": "BG001", "value": "65.6", "spread": "6.4"}, {"groupId": "BG002", "value": "NA", "spread": "NA", "comment": "Combined baseline demographic data were not calculated for Parts 1 and 2 of the study, which included separate patient populations (NA)"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "16"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "38"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "The Number of Participants With Mild Persistent Asthma (Part 1) and COPD (Part 2) With at Least 1 Treatment-emergent Adverse Event", "description": "An adverse event is the development of an undesirable medical condition, or the deterioration of a pre-existing medical condition, following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. An undesirable medical condition can be symptoms, signs, or the abnormal results of laboratory parameters (haematology, blood chemistry, urinalysis, physical examination, 12-lead ECGs and telemetry, and vital signs). AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 18.1.", "populationDescription": "Safety population: all randomized subjects who received at least 1 dose of the investigational product.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From the time of informed consent up to 14 (\u00b12) days after the last dose of investigational product. Unresolved AEs were followed up by the investigator for as long as medically indicated.", "groups": [{"id": "OG000", "title": "AZD8871 50 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG001", "title": "AZD8871 200 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG002", "title": "AZD8871 400 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG003", "title": "AZD8871 900 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG004", "title": "AZD8871 1800 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG005", "title": "AZD8871 2100 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG006", "title": "Placebo (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG007", "title": "AZD8871 400 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG008", "title": "AZD8871 1800 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG009", "title": "Indacaterol 150 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Onbrez Breezhaler\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG010", "title": "Tiotropium 18 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by HandiHaler\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG011", "title": "Placebo (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "6"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "5"}, {"groupId": "OG006", "value": "12"}, {"groupId": "OG007", "value": "34"}, {"groupId": "OG008", "value": "31"}, {"groupId": "OG009", "value": "32"}, {"groupId": "OG010", "value": "30"}, {"groupId": "OG011", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "3"}, {"groupId": "OG004", "value": "3"}, {"groupId": "OG005", "value": "2"}, {"groupId": "OG006", "value": "7"}, {"groupId": "OG007", "value": "18"}, {"groupId": "OG008", "value": "7"}, {"groupId": "OG009", "value": "12"}, {"groupId": "OG010", "value": "11"}, {"groupId": "OG011", "value": "11"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With Clinically Relevant Abnormalities in Blood Pressure", "description": "Blood pressure (BP) measurements (diastolic \\[DBP\\] and systolic BP \\[SBP\\]) taken after \\~5 minutes rest in supine position, at screening, baseline (\u22641 hour before IP administration), 10 and 30 minutes, 1, 2, 3, 4, 8, 12 hours (Day 1) and 24 and 36 hours (Day 2) after IP administration. Normal BP at screening: SBP 100-140 mmHg (subjects aged \u226459 years) and 100-150 mmHg (subjects aged \u226560 years), and DBP 40-90 mmHg.\n\nCriteria for notable changes in BP:\n\nHigh SBP: (\u2265180 and increase over baseline (predose) \u226520) or (\u2265200 and baseline \\<200) Low SBP: (\u2264 90 and decrease over baseline \u226520) or (\u226475 and baseline \\>75) High DBP: (\u2265105 and increase over baseline \u226515) or (\u2265115 and baseline \\<115) Low DBP: (\u226450 and decrease over baseline \u226515) or (\u226440 and baseline \\>40) All out of range values were flagged to the principal investigator who assessed clinical relevance based on medical criteria at individual subject level. Clinically relevant findings were assessed until considered non-clinically relevant.", "populationDescription": "Safety population: all randomized subjects who received at least 1 dose of the investigational product", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From the time of informed consent up to 36 hours after last dose of IP.", "groups": [{"id": "OG000", "title": "AZD8871 50 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG001", "title": "AZD8871 200 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG002", "title": "AZD8871 400 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG003", "title": "AZD8871 900 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG004", "title": "AZD8871 1800 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG005", "title": "AZD8871 2100 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG006", "title": "Placebo (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG007", "title": "AZD8871 400 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG008", "title": "AZD8871 1800 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG009", "title": "Indacaterol 150 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Onbrez Breezhaler\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG010", "title": "Tiotropium 18 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by HandiHaler\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG011", "title": "Placebo (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "6"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "5"}, {"groupId": "OG006", "value": "12"}, {"groupId": "OG007", "value": "34"}, {"groupId": "OG008", "value": "31"}, {"groupId": "OG009", "value": "32"}, {"groupId": "OG010", "value": "30"}, {"groupId": "OG011", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0", "spread": "8.7"}, {"groupId": "OG001", "value": "0", "spread": "2.1"}, {"groupId": "OG002", "value": "0", "spread": "4.3"}, {"groupId": "OG003", "value": "0", "spread": "7.2"}, {"groupId": "OG004", "value": "0", "spread": "3.4"}, {"groupId": "OG005", "value": "0", "spread": "11.7"}, {"groupId": "OG006", "value": "0", "spread": "5.7"}, {"groupId": "OG007", "value": "0", "spread": "8.3"}, {"groupId": "OG008", "value": "0", "spread": "4.5"}, {"groupId": "OG009", "value": "0", "spread": "6.3"}, {"groupId": "OG010", "value": "0", "spread": "6.8"}, {"groupId": "OG011", "value": "0", "spread": "9.6"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With Clinically Relevant Abnormalities in Electrocardiograms (HR, QTcF and Other ECG Parameters).", "description": "HR, QTcF and other ECG abnormalities were assessed by local digital 12-lead ECG performed in triplicate at the time points indicated:\n\nECG (Parts 1 and 2) was assessed at Screening, Day 1 baseline, 10 min, 30 min, 1 hour (h), 2 h, 3 h, 4 h, 8 h, 12 h, 24 h, 36 h after dosing.\n\nTelemetry (Part 1), assessed with at least 2 lead real time display, was recorded at Day -1 (4-6 hours continuous recording, at the time this was more convenient for the logistics of the unit) and on Day 1 from the time of the IP administration up to at least 24 hours, but if advised by the Investigator or designee, then up to 36 hours after IP administration.\n\nAbnormal findings were flagged to the principal investigator who assessed clinical relevance based on medical criteria at individual subject level. Clinically relevant findings were assessed until the abnormality was considered non-clinically relevant.", "populationDescription": "Safety population: all randomized subjects who received at least 1 dose of the investigational product", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From the time of informed consent up to 36 hours after last dose of IP.", "groups": [{"id": "OG000", "title": "AZD8871 50 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG001", "title": "AZD8871 200 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG002", "title": "AZD8871 400 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG003", "title": "AZD8871 900 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG004", "title": "AZD8871 1800 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG005", "title": "AZD8871 2100 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG006", "title": "Placebo (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG007", "title": "AZD8871 400 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG008", "title": "AZD8871 1800 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG009", "title": "Indacaterol 150 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Onbrez Breezhaler\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG010", "title": "Tiotropium 18 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by HandiHaler\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG011", "title": "Placebo (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "6"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "5"}, {"groupId": "OG006", "value": "12"}, {"groupId": "OG007", "value": "34"}, {"groupId": "OG008", "value": "31"}, {"groupId": "OG009", "value": "32"}, {"groupId": "OG010", "value": "30"}, {"groupId": "OG011", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0", "spread": "4.5"}, {"groupId": "OG001", "value": "0", "spread": "3.9"}, {"groupId": "OG002", "value": "0", "spread": "3.7"}, {"groupId": "OG003", "value": "0", "spread": "3.2"}, {"groupId": "OG004", "value": "0", "spread": "5.2"}, {"groupId": "OG005", "value": "0", "spread": "4.8"}, {"groupId": "OG006", "value": "0", "spread": "6.2"}, {"groupId": "OG007", "value": "0", "spread": "6.2"}, {"groupId": "OG008", "value": "0", "spread": "7.7"}, {"groupId": "OG009", "value": "0", "spread": "5.5"}, {"groupId": "OG010", "value": "0", "spread": "4.7"}, {"groupId": "OG011", "value": "0", "spread": "6.1"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With Clinically Relevant Abnormalities in Clinical Biochemistry, Hematology and Urinalysis", "description": "A composite of clinically relevant abnormalities in clinical biochemistry, hematology and urinalysis laboratory evaluations. Laboratory tests (haematology, blood chemistry, and urinalysis) were performed at screening, at Day -1 (Part 1 only), at 24 hours (Day 2) and at follow-up (7 \\[\u00b12\\] days) after IP administration. Coagulation was only performed at screening; TSH, T4 only at screening, at Day-1 and at follow-up.\n\nAbnormal findings were flagged to the principal investigator who assessed clinical relevance based on medical criteria at individual subject level. Clinically relevant findings were assessed until the abnormality was considered non-clinically relevant.", "populationDescription": "Safety population: all randomized subjects who received at least 1 dose of the investigational product", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From the time of informed consent up to 7 days after the last dose of IP.", "groups": [{"id": "OG000", "title": "AZD8871 50 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG001", "title": "AZD8871 200 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG002", "title": "AZD8871 400 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG003", "title": "AZD8871 900 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG004", "title": "AZD8871 1800 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG005", "title": "AZD8871 2100 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG006", "title": "Placebo (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG007", "title": "AZD8871 400 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG008", "title": "AZD8871 1800 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG009", "title": "Indacaterol 150 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Onbrez Breezhaler\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG010", "title": "Tiotropium 18 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by HandiHaler\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG011", "title": "Placebo (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "6"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "5"}, {"groupId": "OG006", "value": "12"}, {"groupId": "OG007", "value": "34"}, {"groupId": "OG008", "value": "31"}, {"groupId": "OG009", "value": "32"}, {"groupId": "OG010", "value": "30"}, {"groupId": "OG011", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}, {"groupId": "OG008", "value": "0"}, {"groupId": "OG009", "value": "0"}, {"groupId": "OG010", "value": "0"}, {"groupId": "OG011", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) on Day 2", "description": "Pharmacodynamics of AZD8871 before (-45 min and -15 min pre-dose) and after single dosing of AZD8871 Forced expiratory volume in 1 second (FEV1) on Day 2 (defined as the average of the values 23:00 and 24:00 hours after the morning dose of investigational product)", "populationDescription": "The PP population is defined as all randomised subjects who satisfied the main I/E criteria, received IP, completed at least 1 treatment period, and did not present major violations to the protocol", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters", "timeFrame": "Baseline (Day 1) to 36 hours post-dose (Day 2)", "groups": [{"id": "OG000", "title": "AZD8871 50 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG001", "title": "AZD8871 200 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG002", "title": "AZD8871 400 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG003", "title": "AZD8871 900 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG004", "title": "AZD8871 1800 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG005", "title": "AZD8871 2100 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG006", "title": "Placebo (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG007", "title": "AZD8871 400 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG008", "title": "AZD8871 1800 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG009", "title": "Indacaterol 150 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Onbrez Breezhaler\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG010", "title": "Tiotropium 18 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by HandiHaler\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG011", "title": "Placebo (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "6"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "5"}, {"groupId": "OG006", "value": "12"}, {"groupId": "OG007", "value": "34"}, {"groupId": "OG008", "value": "31"}, {"groupId": "OG009", "value": "32"}, {"groupId": "OG010", "value": "30"}, {"groupId": "OG011", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.0375", "spread": "0.3449"}, {"groupId": "OG001", "value": "0.2183", "spread": "0.1631"}, {"groupId": "OG002", "value": "0.2883", "spread": "0.1418"}, {"groupId": "OG003", "value": "0.1858", "spread": "0.3528"}, {"groupId": "OG004", "value": "0.3275", "spread": "0.0708"}, {"groupId": "OG005", "value": "0.4630", "spread": "0.2065"}, {"groupId": "OG006", "value": "-0.0600", "spread": "0.3099"}, {"groupId": "OG007", "value": "0.0738", "spread": "0.1212"}, {"groupId": "OG008", "value": "0.1731", "spread": "0.1761"}, {"groupId": "OG009", "value": "0.1036", "spread": "0.1286"}, {"groupId": "OG010", "value": "0.1055", "spread": "0.1922"}, {"groupId": "OG011", "value": "-0.0294", "spread": "0.0768"}]}]}], "analyses": [{"groupIds": ["OG007", "OG011"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "paramType": "Least Square Mean", "paramValue": "0.111", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.0585", "ciUpperLimit": "0.163", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0265"}, {"groupIds": ["OG008", "OG011"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "paramType": "Least square mean", "paramValue": "0.210", "ciPctValue": "95", "ciLowerLimit": "0.156", "ciUpperLimit": "0.264", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0272"}]}, {"type": "SECONDARY", "title": "Cmax of AZD8871 in Parts 1 and 2", "description": "Cmax (maximum observed plasma drug concentrations) of AZD8871 on Day 1 of each treatment period.", "populationDescription": "Pharmacokinetic population: defined as all randomised subjects who have received at least 1 dose of investigational product in at least 1 treatment period and have evaluable PK parameters. AZD8871 plasma PK assessed following dosing with AZD8871 only (not placebo, indacaterol, or tiotropium).", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "pg/mL", "timeFrame": "Pre-dose, and 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h, and 36 h (Day 2) post-dose", "groups": [{"id": "OG000", "title": "AZD8871 50 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG001", "title": "AZD8871 200 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG002", "title": "AZD8871 400 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG003", "title": "AZD8871 900 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG004", "title": "AZD8871 1800 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG005", "title": "AZD8871 2100 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG006", "title": "Placebo (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG007", "title": "AZD8871 400 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG008", "title": "AZD8871 1800 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG009", "title": "Indacaterol 150 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Onbrez Breezhaler\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG010", "title": "Tiotropium 18 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by HandiHaler\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG011", "title": "Placebo (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "6"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "5"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "18"}, {"groupId": "OG008", "value": "15"}, {"groupId": "OG009", "value": "0"}, {"groupId": "OG010", "value": "0"}, {"groupId": "OG011", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "34.77", "spread": "60.77"}, {"groupId": "OG001", "value": "174.1", "spread": "43.74"}, {"groupId": "OG002", "value": "313.4", "spread": "46.56"}, {"groupId": "OG003", "value": "797.3", "spread": "20.99"}, {"groupId": "OG004", "value": "1351", "spread": "20.32"}, {"groupId": "OG005", "value": "1243", "spread": "24.33"}, {"groupId": "OG007", "value": "199.3", "spread": "37.40"}, {"groupId": "OG008", "value": "810.8", "spread": "36.59"}]}]}]}, {"type": "SECONDARY", "title": "Tmax of AZD8871 in Parts 1 and 2", "description": "tmax (time to reach maximum concentration) of AZD8871 on Day 1 of each treatment period.", "populationDescription": "Pharmacokinetic population: defined as all randomised subjects who have received at least 1 dose of investigational product in at least 1 treatment period and have evaluable PK parameters. AZD8871 plasma PK assessed following dosing with AZD8871 only (not placebo, indacaterol, or tiotropium).", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Hours", "timeFrame": "Pre-dose, and 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h, and 36 h (Day 2) post-dose", "groups": [{"id": "OG000", "title": "AZD8871 50 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG001", "title": "AZD8871 200 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG002", "title": "AZD8871 400 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG003", "title": "AZD8871 900 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG004", "title": "AZD8871 1800 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG005", "title": "AZD8871 2100 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG006", "title": "Placebo (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG007", "title": "AZD8871 400 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG008", "title": "AZD8871 1800 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG009", "title": "Indacaterol 150 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Onbrez Breezhaler\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG010", "title": "Tiotropium 18 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by HandiHaler\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG011", "title": "Placebo (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "6"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "5"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "18"}, {"groupId": "OG008", "value": "15"}, {"groupId": "OG009", "value": "0"}, {"groupId": "OG010", "value": "0"}, {"groupId": "OG011", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.88", "lowerLimit": "0.52", "upperLimit": "1.03"}, {"groupId": "OG001", "value": "0.86", "lowerLimit": "0.48", "upperLimit": "1.00"}, {"groupId": "OG002", "value": "1.00", "lowerLimit": "0.75", "upperLimit": "1.05"}, {"groupId": "OG003", "value": "1.00", "lowerLimit": "0.98", "upperLimit": "1.02"}, {"groupId": "OG004", "value": "1.49", "lowerLimit": "0.73", "upperLimit": "2.03"}, {"groupId": "OG005", "value": "1.02", "lowerLimit": "1.00", "upperLimit": "2.00"}, {"groupId": "OG007", "value": "1.00", "lowerLimit": "0.75", "upperLimit": "3.00"}, {"groupId": "OG008", "value": "2.00", "lowerLimit": "0.75", "upperLimit": "3.00"}]}]}]}, {"type": "SECONDARY", "title": "AUC(0-t) of AZD8871 in Parts 1 and 2", "description": "AUC(0-t) (area under the concentration-time curve from time zero to time of the last quantifiable measurable concentration) of AZD8871 on Day 1 of each treatment period.", "populationDescription": "Pharmacokinetic population: defined as all randomised subjects who have received at least 1 dose of investigational product in at least 1 treatment period and have evaluable PK parameters. AZD8871 plasma PK assessed following dosing with AZD8871 only (not placebo, indacaterol, or tiotropium).", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "pg*h/mL", "timeFrame": "Pre-dose, and 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h, and 36 h (Day 2) post-dose", "groups": [{"id": "OG000", "title": "AZD8871 50 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG001", "title": "AZD8871 200 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG002", "title": "AZD8871 400 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG003", "title": "AZD8871 900 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG004", "title": "AZD8871 1800 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG005", "title": "AZD8871 2100 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG006", "title": "Placebo (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG007", "title": "AZD8871 400 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG008", "title": "AZD8871 1800 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG009", "title": "Indacaterol 150 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Onbrez Breezhaler\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG010", "title": "Tiotropium 18 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by HandiHaler\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG011", "title": "Placebo (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "6"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "5"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "16"}, {"groupId": "OG008", "value": "15"}, {"groupId": "OG009", "value": "0"}, {"groupId": "OG010", "value": "0"}, {"groupId": "OG011", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "110", "spread": "69.17"}, {"groupId": "OG001", "value": "631.3", "spread": "30.40"}, {"groupId": "OG002", "value": "1397", "spread": "31.41"}, {"groupId": "OG003", "value": "3299", "spread": "27.00"}, {"groupId": "OG004", "value": "6055", "spread": "24.98"}, {"groupId": "OG005", "value": "6418", "spread": "35.13"}, {"groupId": "OG007", "value": "1239", "spread": "37.70"}, {"groupId": "OG008", "value": "6159", "spread": "44.30"}]}]}]}, {"type": "SECONDARY", "title": "AUC(0-24) of AZD8871 in Parts 1 and 2", "description": "AUC(0-24) (area under the concentration-time curve from zero to 24h) of AZD8871 on Day 1 of each treatment period.", "populationDescription": "Pharmacokinetic population: defined as all randomised subjects who have received at least 1 dose of investigational product in at least 1 treatment period and have evaluable PK parameters. AZD8871 plasma PK assessed following dosing with AZD8871 only (not placebo, indacaterol, or tiotropium).", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "pg*h/mL", "timeFrame": "Pre-dose, and 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h, and 36 h (Day 2) post-dose", "groups": [{"id": "OG000", "title": "AZD8871 50 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG001", "title": "AZD8871 200 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG002", "title": "AZD8871 400 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG003", "title": "AZD8871 900 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG004", "title": "AZD8871 1800 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG005", "title": "AZD8871 2100 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG006", "title": "Placebo (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG007", "title": "AZD8871 400 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG008", "title": "AZD8871 1800 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG009", "title": "Indacaterol 150 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Onbrez Breezhaler\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG010", "title": "Tiotropium 18 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by HandiHaler\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG011", "title": "Placebo (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "6"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "5"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "18"}, {"groupId": "OG008", "value": "15"}, {"groupId": "OG009", "value": "0"}, {"groupId": "OG010", "value": "0"}, {"groupId": "OG011", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "118.9", "spread": "60.19"}, {"groupId": "OG001", "value": "567.9", "spread": "29.74"}, {"groupId": "OG002", "value": "1265", "spread": "32.44"}, {"groupId": "OG003", "value": "3020", "spread": "25.71"}, {"groupId": "OG004", "value": "5587", "spread": "25.40"}, {"groupId": "OG005", "value": "5922", "spread": "34.32"}, {"groupId": "OG007", "value": "1195", "spread": "38.91"}, {"groupId": "OG008", "value": "5659", "spread": "43.68"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "AUC of AZD8871 in Parts 1 and 2", "description": "AUC (area under the concentration-time curve from time 0 to infinity) of AZD8871 on Day 1 of each treatment period", "populationDescription": "Pharmacokinetic population: defined as all randomised subjects who have received at least 1 dose of investigational product in at least 1 treatment period and have evaluable PK parameters. AZD8871 plasma PK assessed following dosing with AZD8871 only (not placebo, indacaterol, or tiotropium).", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "pg*h/mL", "timeFrame": "Predose, and 5 min, 15 min, 30 min, and 45 min, at 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h and 36 h (Day 2) post-dose", "groups": [{"id": "OG000", "title": "AZD8871 50 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG001", "title": "AZD8871 200 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG002", "title": "AZD8871 400 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG003", "title": "AZD8871 900 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG004", "title": "AZD8871 1800 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG005", "title": "AZD8871 2100 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG006", "title": "Placebo (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG007", "title": "AZD8871 400 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG008", "title": "AZD8871 1800 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG009", "title": "Indacaterol 150 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Onbrez Breezhaler\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG010", "title": "Tiotropium 18 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by HandiHaler\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG011", "title": "Placebo (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "6"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "5"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "18"}, {"groupId": "OG008", "value": "15"}, {"groupId": "OG009", "value": "0"}, {"groupId": "OG010", "value": "0"}, {"groupId": "OG011", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "123.1", "spread": "75.48"}, {"groupId": "OG001", "value": "774.5", "spread": "32.64"}, {"groupId": "OG002", "value": "1671", "spread": "28.54"}, {"groupId": "OG003", "value": "3831", "spread": "28.72"}, {"groupId": "OG004", "value": "6941", "spread": "22.23"}, {"groupId": "OG005", "value": "7164", "spread": "34.10"}, {"groupId": "OG007", "value": "1459", "spread": "39.19"}, {"groupId": "OG008", "value": "6769", "spread": "44.65"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Elimination Half-life of AZD8871 in Parts 1 and 2", "description": "Elimination half-life (t\u00bd\u03bbz) for AZD8871 on Day 1 of each treatment period. t\u00bd\u03bbz was generally calculated over a period of less than 3 times the resultant half-life", "populationDescription": "Pharmacokinetic population: defined as all randomised subjects who have received at least 1 dose of investigational product in at least 1 treatment period and have evaluable PK parameters. AZD8871 plasma PK assessed following dosing with AZD8871 only (not placebo, indacaterol, or tiotropium).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Hours", "timeFrame": "Predose, and 5 min, 15 min, 30 min, and 45 min, at 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h (Day 1), 24 h and 36 h (Day 2) post-dose", "groups": [{"id": "OG000", "title": "AZD8871 50 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG001", "title": "AZD8871 200 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG002", "title": "AZD8871 400 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG003", "title": "AZD8871 900 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG004", "title": "AZD8871 1800 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG005", "title": "AZD8871 2100 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG006", "title": "Placebo (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG007", "title": "AZD8871 400 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG008", "title": "AZD8871 1800 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG009", "title": "Indacaterol 150 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Onbrez Breezhaler\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG010", "title": "Tiotropium 18 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by HandiHaler\u00ae single-dose dry powder inhaler (DPI)"}, {"id": "OG011", "title": "Placebo (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "6"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "5"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "18"}, {"groupId": "OG008", "value": "15"}, {"groupId": "OG009", "value": "0"}, {"groupId": "OG010", "value": "0"}, {"groupId": "OG011", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.439", "spread": "7.350"}, {"groupId": "OG001", "value": "23.10", "spread": "2.809"}, {"groupId": "OG002", "value": "20.81", "spread": "5.384"}, {"groupId": "OG003", "value": "18.86", "spread": "3.959"}, {"groupId": "OG004", "value": "19.29", "spread": "5.468"}, {"groupId": "OG005", "value": "15.96", "spread": "2.789"}, {"groupId": "OG007", "value": "14.20", "spread": "5.521"}, {"groupId": "OG008", "value": "12.89", "spread": "2.268"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From the time of informed consent up to 14 (\u00b12) days after the last dose of investigational product (IP). Treatment-emergent adverse events were those reported after the first dose of IP up to 14 (\u00b12) days after the last dose of IP. Unresolved AEs were followed up by the investigator for as long as medically indicated.", "description": "The Safety population comprised all randomised subjects who received at least 1 dose of the IP.", "eventGroups": [{"id": "EG000", "title": "AZD8871 50 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)", "seriousNumAffected": 0, "seriousNumAtRisk": 6, "otherNumAffected": 5, "otherNumAtRisk": 6}, {"id": "EG001", "title": "AZD8871 200 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)", "seriousNumAffected": 0, "seriousNumAtRisk": 6, "otherNumAffected": 5, "otherNumAtRisk": 6}, {"id": "EG002", "title": "AZD8871 400 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)", "seriousNumAffected": 0, "seriousNumAtRisk": 6, "otherNumAffected": 3, "otherNumAtRisk": 6}, {"id": "EG003", "title": "AZD8871 900 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)", "seriousNumAffected": 0, "seriousNumAtRisk": 6, "otherNumAffected": 3, "otherNumAtRisk": 6}, {"id": "EG004", "title": "AZD8871 1800 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)", "seriousNumAffected": 0, "seriousNumAtRisk": 6, "otherNumAffected": 3, "otherNumAtRisk": 6}, {"id": "EG005", "title": "AZD8871 2100 \u03bcg (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)", "seriousNumAffected": 0, "seriousNumAtRisk": 5, "otherNumAffected": 2, "otherNumAtRisk": 5}, {"id": "EG006", "title": "Placebo (Part 1)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)", "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 12, "otherNumAtRisk": 12}, {"id": "EG007", "title": "AZD8871 400 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)", "seriousNumAffected": 1, "seriousNumAtRisk": 34, "otherNumAffected": 8, "otherNumAtRisk": 34}, {"id": "EG008", "title": "AZD8871 1800 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)", "seriousNumAffected": 0, "seriousNumAtRisk": 31, "otherNumAffected": 4, "otherNumAtRisk": 31}, {"id": "EG009", "title": "Indacaterol 150 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by Onbrez Breezhaler\u00ae single-dose dry powder inhaler (DPI)", "seriousNumAffected": 0, "seriousNumAtRisk": 32, "otherNumAffected": 6, "otherNumAtRisk": 32}, {"id": "EG010", "title": "Tiotropium 18 \u03bcg (Part 2)", "description": "Single-dose, oral inhalation by HandiHaler\u00ae single-dose dry powder inhaler (DPI)", "seriousNumAffected": 1, "seriousNumAtRisk": 30, "otherNumAffected": 8, "otherNumAtRisk": 30}, {"id": "EG011", "title": "Placebo (Part 2)", "description": "Single-dose, oral inhalation by Genuair\u00ae single-dose dry powder inhaler (DPI)", "seriousNumAffected": 0, "seriousNumAtRisk": 32, "otherNumAffected": 8, "otherNumAtRisk": 32}], "seriousEvents": [{"term": "Spinal fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 1, "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Physical assault", "organSystem": "Social circumstances", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 2, "numAffected": 2, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 1, "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 2, "numAffected": 2, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 1, "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 3, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 3, "numAffected": 3, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 5, "numAffected": 5, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 4, "numAffected": 3, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 4, "numAffected": 4, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 7, "numAffected": 7, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 7, "numAffected": 7, "numAtRisk": 32}]}, {"term": "Chronic obstructive pulmonary disorder", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 2, "numAffected": 2, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 1, "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Ear pain", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Feeling hot", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Catheter site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 4, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Seasonal allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Abscess oral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Oral herpes", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Bronchitis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Neck pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Dizziness postural", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Presyncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Wheezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Productive cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Skin irritation", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG010", "numEvents": 0, "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG011", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Publication of the results by the Principal Investigator (PI) will be subject to mutual agreement between the PI and the sponsor."}, "pointOfContact": {"title": "Study Director", "organization": "AstraZeneca", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M23449", "name": "Pulmonary Disease, Chronic Obstructive", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069447", "term": "Tiotropium Bromide"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000010276", "term": "Parasympatholytics"}, {"id": "D000018680", "term": "Cholinergic Antagonists"}, {"id": "D000018678", "term": "Cholinergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M416", "name": "Tiotropium Bromide", "asFound": "Melanoma", "relevance": "HIGH"}, {"id": "M5241", "name": "Bromides", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M13189", "name": "Parasympatholytics", "relevance": "LOW"}, {"id": "M20760", "name": "Cholinergic Antagonists", "relevance": "LOW"}, {"id": "M20758", "name": "Cholinergic Agents", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AntiConv", "name": "Anticonvulsants"}]}}, "hasResults": true}